Biohaven, a biopharma engaged in identifying and developing clinical-stage compounds targeting the glutamatergic system, has completed an oversubscribed $80 million financing. Venrock led the investment, which also saw participation from Vivo Capital, Aisling Capital and Osage University Partners, among others. Proceeds from the round will be used to advance the company’s late-stage clinical programs in orphan neurologic indications and other trials.
Interested in VC investment in the healthcare space? Check out our recent post highlighting the trend of large venture rounds for healthcare companies in 2016.